Hunan Fangsheng Huamei Medical Technology

Hunan Fangsheng Huamei Pharmaceutical Technology is a clinical-stage biotechnology company based in Changsha, China, focused on the discovery and development of innovative small molecule therapeutics. As a specialized R&D subsidiary of Hunan Fangsheng Pharmaceutical, the company primarily targets oncology, autoimmune disorders, and metabolic diseases. Its lead candidate, FSH-167, is a potent c-Met inhibitor currently in Phase 2 clinical trials for the treatment of solid tumors, including non-small cell lung cancer. The company also advances FSH-103, a Janus kinase (JAK) inhibitor, aimed at treating inflammatory conditions like rheumatoid arthritis. Fangsheng Huamei leverages its integrated research platform to transition high-potential candidates from early discovery through complex clinical evaluation.